Citations

Clear

5 citation(s) found for "Kaur, Anmolpreet".

Artificial Intelligence Enabled Dielectric Fingerprinting of Arrhythmogenic Substrates: A Precision Paradigm for Tissue Characterization Guided Cardiac Electrophysiology
Arunachalam, S P , Shariff, Mohammad Naveed , Kathirvel, Bargavi , Saraboji, Kaaviyashri , Kaur, Anmolpreet , Krishnappa, Manjunath, Elangovan, Poonguzhali , Jerold Wilson, Sancia Mary, Jayapradhaban Kala, Jayavinamika, Dey, Shuvashis , Mitra, Dipankar , Karuppiah, Shiva Sankari, Helgeson, Scott A , Tolkacheva, E G

Mayo Clinic

Sensors | September 25, 2026 | Volume: 26 | Issue: 19 | Pages: 6090

10.3390/s26196090 | PMID 42884291 Get It

Background: Electrical and dielectric properties of the myocardium depend on its composition, fibrosis, edema, ischemia, and heat damage, and hence may play an important role in defining the electrophysiologic substrate. Local impedance and other impedance-based methods give information about these parameters that is available to clinicians, but not direct or substitutable for intrinsic conductivity and permittivity of the tissue. The use of artificial intelligence has been thoroughly studied for the ECGs, electrograms, images, and computational data analysis, but not for dielectric or impedance measurements. Objective: The study aims to review the scientific basis of dielectric properties of heart muscle critically in cardiology and electrophysiology, to differentiate between existing clinical and conceptual applications of myocardial dielectrics, and to estimate current and potential contributions of artificial intelligence to their interpretation. Data Sources and Study Selection: The current work represents a structured narrative review in PubMed, Scopus, and Google Scholar databases from inception until May 2026 based on various combinations of keywords that refer to myocardial impedance, dielectric properties, conductivity, permittivity, local impedance, dielectric imaging, cardiac electrophysiology, catheter ablation, machine learning, and artificial intelligence. This review included experimental, ex vivo, animal, computational, and human studies related to myocardial dielectric properties and their use in electrophysiology. Evidence was classified according to four categories: direct human clinical evidence; preclinical/translation evidence; indirect evidence from related techniques; and extrapolation concept. As a result of heterogeneity between studies, sensing technologies, and outcomes, the results have been analyzed narratively. Key Findings: Evidence regarding the usage of AI algorithms, which have been primarily trained on myocardial dielectric or catheter-based local impedance data, is extremely scarce and mostly consists of preclinical or ex vivo data. On the contrary, the majority of clinically used AI algorithms in the field of electrophysiology make use of ECG data, intracardiac electrogram data, image processing, or computational modeling without any inputs related to dielectrics or local impedance. Conclusions and Implications for Practice: Dielectric sensing is an attractive supplement to traditional methods of voltage mapping and imaging, although the clinical readiness of dielectric sensing greatly varies depending on the application. At the present time, the existing data provide a basis for utilizing the local impedance measurement in the ablation procedure and evaluation of the myocardium properties, while the combination of artificial intelligence and dielectric sensing is still experimental. Before being introduced into the clinical electrophysiology practice, signal acquisition standardization and prospective multicenter trials are needed.
Artificial Intelligence Enabled Diagnostics Using Photoplethysmography (PPG): Beyond SpO2 and Heart Rate
Joshi, Divya Dinesh, Saraboji, Kaaviyashri , Shaik, Asiya Tasleema , Sakalabaktula, Krishna Sai Kiran, Purohit, Shreya, Godugu, Swathi , Nirmal, Jasmine , Kayarkar, Riya, Correa, Bernardo Henrique Mendes , Gangidi, Namratha , Yadav, Pratibha, Yadav, Jyoti , Farook, Farshi , LEE, JIEUN , Shariff, Mohammed Naveed , Sundaram, Divaakar Siva Baala, Yerrapragada, Gayathri, Elangovan, Poonguzhali , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Wilson, Sancia Mary Jerold, Karuppiah, Shiva Sankari, Abbasi, Zoma, Rapolu, Swetha, Bumrah, Simardeep Kaur, Bilgaiyan, Rashi, Premkumar, Chandra Rupini , Kaur, Anmolpreet , Pugalenthi, Lakshmi Sree , Sood, Divyanshi, Shivaram, Suganti, Iyer, Vivek , Vidhya, C. M., Masihi, Simin, Helgeson, Scott A. , Arunachalam, Shivaram P. , Natarajan, Thangeswaran , Jerold Wilson, Sancia Mary, Iyer, Vivek N , C M, Vidhya, Elangovan, Poonguzhali , Arunachalam, S P , Helgeson, Scott A , Shariff, Mohammad Naveed , Sakalabaktula, Krishna Sai Kiran , Godugu, Swathi , Yerrapragada, Gayathri, Bumrah, Simardeep Kaur, Bilgaiyan, Rashi , Shivaram, Suganti, Masihi, Simin

Mayo Clinic

Life | September 15, 2026 | Volume: 16 | Issue: 9 | Pages: 1530

10.3390/life16091530 | PMID 42795395 Get It

Photoplethysmography (PPG) is a non-invasive optical technique commonly used to measure heart rate and oxygen saturation, but its waveform contains additional physiological information that can be analyzed using artificial intelligence (AI). This narrative review summarizes the emerging applications of AI-based PPG in cardiovascular, respiratory, sleep, hemodynamic, pregnancy-related, and portal-hypertension assessment, with the aim of evaluating its potential beyond conventional monitoring and identifying barriers to clinical translation. The literature search was conducted using PubMed, Google Scholar, IEEE Xplore, ScienceDirect, and SpringerLink. Additional relevant studies were identified through screening the reference lists of included articles. Studies published between 2002 and 2026 were identified to capture the development of PPG from conventional monitoring to newer AI-based applications. Human studies were prioritized, while relevant computational, simulated, synthetic, ex vivo, and technical studies were also included. Studies unrelated to PPG, duplicates, and studies with limited relevance were excluded. A total of 96 references were included, covering AI approaches such as convolutional and deep neural networks, ensemble methods, transfer learning, U-Net, generative adversarial networks, and Transformer-based models. Overall, the reviewed evidence suggests that AI-based PPG may support blood pressure estimation, atrial fibrillation detection, sleep and respiratory monitoring, vascular aging assessment, pulmonary hypertension screening, preeclampsia assessment, volume-status and compensatory-reserve assessment, and exploratory assessment related to portal hypertension. However, clinical translation remains limited by motion artifacts, sensor and measurement-site variability, skin-pigmentation-related bias, physiological and environmental influences, heterogeneous methods, limited external validation, and inconsistent clinical and regulatory standards.
Operationalizing WHO Ethical Principles for Healthcare AI: A Lifecycle-Aligned Governance-by-Design Framework
Saraboji, Kaaviyashri , Gopalakrishnan, Keerthy, Sood, Divyanshi, Kaur, Anmolpreet , Shivaram, Suganti, Helgeson, Scott A. , Arunachalam, Shivaram P. , Mitra, Dipankar , Kaur, Anmolpreet , Arunachalam, S P , Helgeson, Scott A

Mayo Clinic

AI in Medicine | June 10, 2026 | Volume: 1 | Issue: 2 | Pages: 16

10.3390/aimed1020016 Get It

Artificial intelligence (AI) is rapidly transforming healthcare through applications in clinical decision support, diagnostic imaging, population health management, and workflow optimization. Despite these advances, real-world deployment continues to expose critical challenges related to safety, bias, transparency, and integration into clinical workflows. Algorithmic bias can exacerbate health disparities, limited explainability may undermine clinician trust, and insufficient validation and post-deployment monitoring can compromise patient safety. Although the World Health Organization (WHO) has established six ethical principles for AI in health, including autonomy, well-being and safety, transparency, accountability, equity, and sustainability, translating these high-level principles into practical and enforceable governance mechanisms remains a persistent challenge. This narrative review synthesizes insights from bioethics, health policy, computer science, and clinical medicine to identify gaps in current AI governance approaches and proposes a lifecycle-aligned governance-by-design framework that operationalizes WHO ethical principles across key stages of the healthcare AI lifecycle, including data collection, model development, validation, deployment, and post-deployment monitoring. The framework integrates concrete governance mechanisms such as consent governance, fairness evaluation, external validation, explainability, clinician oversight, and continuous performance monitoring. Overall, this work advances a practical, lifecycle-integrated approach to AI governance and provides a structured foundation for developing safe, equitable, and trustworthy AI systems in healthcare.
Artificial Intelligence-Enhanced Liquid Biopsy and Radiomics in Early-Stage Lung Cancer Detection: A Precision Oncology Paradigm
Cherukuri, Swathi Priya , Kaur, Anmolpreet , Goyal, Bipasha, Kukunoor, Hanisha Reddy , Sahito, Areesh Fatima, Sachdeva, Pratyush , Yerrapragada, Gayathri, Poonguzhali, E. , Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Richard, Samuel, Venkatesaprasath, Shakthidevi Pallikaranai, Karuppiah, Shiva Sankari, Iyer, Vivek , Helgeson, Scott A. , Arunachalam, Shivaram P. , Kaur, Anmolpreet , Natarajan, Thangeswaran , Pallikaranai Venkatesaprasath, Shakthidevi, Iyer, Vivek N , Arunachalam, S P , Helgeson, Scott A , Shariff, Mohammad Naveed , Sahito, Areesh Fatima , Natarajan, Thangeswaran

Mayo Clinic

Cancers | September 29, 2025 | Volume: 17 | Issue: 19 | Pages: 3165

10.3390/cancers17193165 | PMID 41097693 Get It

Background: Lung cancer remains the leading cause of cancer-related mortality globally, largely due to delayed diagnosis in its early stages. While conventional diagnostic tools like low-dose CT and tissue biopsy are routinely used, they suffer from limitations including invasiveness, radiation exposure, cost, and limited sensitivity for early-stage detection. Liquid biopsy, a minimally invasive alternative that captures circulating tumor-derived biomarkers such as ctDNA, cfRNA, and exosomes from body fluids, offers promising diagnostic potential—yet its sensitivity in early disease remains suboptimal. Recent advances in Artificial Intelligence (AI) and radiomics are poised to bridge this gap. Objective: This review aims to explore how AI, in combination with radiomics, enhances the diagnostic capabilities of liquid biopsy for early detection of lung cancer and facilitates personalized monitoring strategies. Content Overview: We begin by outlining the molecular heterogeneity of lung cancer, emphasizing the need for earlier, more accurate detection strategies. The discussion then transitions into liquid biopsy and its key analytes, followed by an in-depth overview of AI techniques—including machine learning (e.g., SVMs, Random Forest) and deep learning models (e.g., CNNs, RNNs, GANs)—that enable robust pattern recognition across multi-omics datasets. The role of radiomics, which quantitatively extracts spatial and morphological features from imaging modalities such as CT and PET, is explored in conjunction with AI to provide an integrative, multimodal approach. This convergence supports the broader vision of precision medicine by integrating omics data, imaging, and electronic health records. Discussion: The synergy between AI, liquid biopsy, and radiomics signifies a shift from traditional diagnostics toward dynamic, patient-specific decision-making. Radiomics contributes spatial information, while AI improves pattern detection and predictive modeling. Despite these advancements, challenges remain—including data standardization, limited annotated datasets, the interpretability of deep learning models, and ethical considerations. A push toward rigorous validation and multimodal AI frameworks is necessary to facilitate clinical adoption. Conclusion: The integration of AI with liquid biopsy and radiomics holds transformative potential for early lung cancer detection. This non-invasive, scalable, and individualized diagnostic paradigm could significantly reduce lung cancer mortality through timely and targeted interventions. As technology and regulatory pathways mature, collaborative research is crucial to standardize methodologies and translate this innovation into routine clinical practice.
Artificial Intelligence-Guided Neuromodulation in Heart Failure with Preserved and Reduced Ejection Fraction: Mechanisms, Evidence, and Future Directions
Ansari, Rabiah Aslam, Senapati, Sidhartha Gautam , Ahluwalia, Vibhor, Panjwani, Gianeshwaree Alias Rachna , Kaur, Anmolpreet , Yerrapragada, Gayathri, Kala, Jayavinamika Jayapradhaban, Poonguzhali, E. , Karuppiah, Shiva Sankari, Asadimanesh, Naghmeh, Muthyala, Anjani, Arunachalam, Shivaram P. , Kaur, Anmolpreet , Jayapradhaban Kala, Jayavinamika, Arunachalam, S P , Panjwani, Gianeshwaree Alias Rachna , Ansari, Rabiah Aslam

Mayo Clinic

Journal of Cardiovascular Development and Disease | August 19, 2025 | Volume: 12 | Issue: 8 | Pages: 314

10.3390/jcdd12080314 | PMID 40863380 Get It

Heart failure, a significant global health burden, is divided into heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), characterized by systolic dysfunction and diastolic stiffness, respectively. While HFrEF benefits from pharmacological and device-based therapies, HFpEF lacks effective treatments, with both conditions leading to high rehospitalization rates and reduced quality of life, especially in older adults with comorbidities. This review explores the role of artificial intelligence (AI) in advancing autonomic neuromodulation for heart failure management. AI enhances patient selection, optimizes stimulation strategies, and enables adaptive, closed-loop systems. In HFrEF, vagus nerve stimulation and baroreflex activation therapy improve functional status and biomarkers, while AI-driven models adjust stimulation dynamically based on physiological feedback. In HFpEF, AI aids in deep phenotyping to identify responsive subgroups for neuromodulatory interventions. Clinical tools support remote monitoring, risk assessment, and symptom detection. However, challenges like data integration, ethical oversight, and clinical adoption limit real-world application. Algorithm transparency, bias minimization, and equitable access are critical for success. Interdisciplinary collaboration and ethical innovation are essential to develop personalized, data-driven, patient-centered heart failure treatment strategies through AI-guided neuromodulation.